Drug Profile

Anti-CD7 CAR T-cell therapy - Guangzhou Bio-gene Technology

Alternative Names: Anti-CD7 chimeric antigen receptor T cells - Guangzhou Bio-gene Technology

Latest Information Update: 29 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Guangzhou Bio-gene Technology
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

29 Jun 2023 Anti-CD7 CAR T-cell therapy - Guangzhou Bio-gene Technology is available for licensing as of 29 Jun 2023. http://gzbiogene.com/english.php/Technology/index
26 Jun 2023 Phase-I/II clinical trials in Precursor T-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater, In children, In adolescents, In adults, Recurrent) in China (IV) (NCT05909527)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com